期刊文献+

氢氯噻嗪固体分散体的制备及其溶出溶解性 被引量:1

Studies on preparation and dissolution of hydrochlorothiazide solid dispersions
原文传递
导出
摘要 目的:采用固体分散技术,提高氢氯噻嗪的体外溶解性能。方法:分别以PEG6000和PVPK30为载体,制备氢氯噻嗪固体分散体。采用紫外分光光度法进行含量测定,差示热分析法鉴别药物在载体中的存在状态,并进行溶解度、体外溶出速率实验。结果:2种载体的固体分散体均能增加药物的溶解度和溶出速率,氢氯噻嗪在载体中以高度分散状态存在。结论:以PVPK30为载体制备的氢氯噻嗪固体分散体体外溶解度和溶出速率明显提高。 OBJECTIVE The solid dispersion method was used to increase the dissolution of hydrochlorothiazide. METHODS Hydrochlorothiazide solid dispersions were prepared respectively with PEG6000 and PVPK30. UV spectrophotometry was used to determine hydrochlorothiazide content. Differential thermal analysis was used to determine the status of hydrochlorothiazide in solid dispersion. The solubility and dissolution rate in vitro were studied. RFSULTS The solubility and dissolution rate of all hydrochlorothiazide solid dispersion were increased. Hydrochlorothiazide were completely dispersed in carrier materials. CONCLUSION The solid dispersion prepared with PVPK30 can increase the solubility and dissolution rate.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2010年第15期1293-1295,共3页 Chinese Journal of Hospital Pharmacy
关键词 氢氯噻嗪 固体分散体 溶解度 溶出速率 差示热分析 hydrochlorothiazide solid dispersion solubility dissolution rate differential thermal analysis
  • 相关文献

参考文献3

  • 1陈新谦 金有豫 汤光.新编药物学[M]15版[M].北京:人民卫生出版社,2003.583.
  • 2陆彬.药物新剂型与新技术[M].北京:人民卫生出版社,2002.212.
  • 3.中国药典二部[S].,2005年版.68.

共引文献568

同被引文献21

  • 1i Chiids S L, Stahly G P, Park A, et al, The malt-cocrystal continuum:the influence of crystal Jtructure on ionization state [J ]. Mol Pharmaeuticl, 2007,4 ( 3 ) : 323-338.
  • 2Fleisehman S G, Kuduva S S, MeMahen J A, etal. Crystal engineering of the eompotdtion of pharmaceutical phases. multiple-component crystalline solidi, involving carbamaz- opine [J], Cryst Growth Dett,2003,3(6):909-919.
  • 3Clarke H D, Amra K K, Bass H, et al. Structure-stability relationships in cocrystal hydrates :does the promiscuity of water make crystalline hydrates the nemesis of crystal en- gineering? [ J I. Cryst Growth Des, 2010, 10 ( 5 ) : 2152- 2167.
  • 4McNamara D P,Childs S L,Giordano J,et al. Use of a glu- taric acid cocrystal to improve oral bioavailability of a low solubility API [ J ]. Pharm Res, 2006,23 ( 8 ) : 1888-1897.
  • 5Zhang Tingting, Wang Haitao, Jia Jiangtao, et al. Syntheses and pharmacokinetics properties of an iloperidone pharma- ceutical cocrystal [ J ]. Inorg Chem Commun, 2014,39: 144-146.
  • 6Takaaki M, Yasuo Y, Etsuo Y, et al. Cocrystallization and amorphization induced by drug-excipient interaction im- proves the physical properties of acyclovir [ J ]. Interna- tional Journal of Pharmaceutics ,2012,422:160-169.
  • 7Irena T, Shyam K, Jag S, et al. Pharmaceutical characteri- sation and evaluation of cocrystals: Importance of in vitro dissolution conditions and type of coformer [ J ]. Intema-tiona] Journ of Pharrneufio,2013,4.53 380-388.
  • 8Yah Yan, (:hen Jiamei, C, eng Na, eta], Improving the tolu- bility of qomelatinv vii cocrystall [ J ], Crytt Growth Des, 2012,12 (5) :2226.2233.
  • 9Karki $, Fri6i T,F0bi L,et a. Improvin6 meehanleal propertiem of cryltalline eolidB by eocryltal formation:now oomprenible forme of paraeetamol [ J] . Advancod Matori- al ,2009,2113905-3909.
  • 10陈新谦.金有豫.汤光.新编药物学[M].15版.北京:人民卫生出版社.2003:90-491.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部